Ingole et al / International Journal of Advances in Scientific Research 2020; 6(5): e5424. e5424 IJASR|VOL 06|ISSUE 06|2020 Page 1 of 4 www.ssjournals.com International Journal of Advances in Scientific Research ISSN: 2395-3616 (Online) Journal DOI: https://doi.org/10.7439/ijasr Review Article Is pre vaccination the reason for less morbidity and mortality for COVID-19 in India: An epidemiological study Ramesh D Ingole 1 , Avinash B. Thalkari 2* and Pawan N. Karwa 3 1 DJP College of Pharmacy Pathri, Dist-Parbhani, Maharashtra, India 2 Vasant Pharmacy College, Kaij, Maharashtra, India 3 Gurukrupa Institute of Pharmacy (DEGREE), Near Chatrapatthi Sugar Factory, NH- 222 Gadi Road, Majalgaon-431131, Maharashtra, India Abstract As we all know the current rapid of the covid-19 in the most of the world has become a pandemic situation. Many research studies have been by various countries to develop vaccines against the coronavirusSARS-CoV-2. Currently about six vaccine candidates have passed early testing and have entered the clinical trials across the globe, along with more than80 other candidates reported to be in preclinical stages. These state that many different approaches are being moved forward at the same time. However, the destinations not yet completed and so no vaccines are currently licensed for any of the other corona viruses affecting humans. If we go in the past few decades, various vaccines were given to geriatrics as well as paediatrics. So if we look the same in other countries the use of the vaccines is very less or instead some countries have no authentic grant to sell or use the vaccines. Here in this present study we are trying to propose that by the early use of the vaccines also reduced the number of reported COVID-19 cases in a country. So is the combination of these vaccines a reason for the reduced morbidity and mortality and can it be a boon to fight against the disaster of COVID-19 in future. Keywords: COVID-19, Vaccines, morbility, mortality, preclinical and clinical testing. *Correspondence Info: Mr. Avinash B. Thalkari, Principal, Vasant Pharmacy College, Kaij, Maharashtra, India *Article History: Received: 19/05/2020 Revised: 28/05/2020 Accepted: 30/05/2020 DOI: https://doi.org/10.7439/ijasr.v6i5.5424 QR Code How to cite: Ingole R. D, Thalkari A. B. and Karwa P. N. Is pre vaccination the reason for less morbidity and mortality for COVID-19 in India: An epidemiological study. International Journal of Advances in Scientific Research 2020; 6(5): e5424. Doi: 10.7439/ijasr.v6i5.5424 Available from: https://ssjournals.com/index.php/ijasr/article/view/5424 Copyright (c) 2020 International Journal of Advances in Scientific Research. This work is licensed under a Creative Commons Attribution 4.0 International License 1. Introduction A group of cases subjecting to pneumonia caused due to a β-coronavirus, occurred in Wuhan, China. Later it was named as the 2019- novel coronavirus (2019-nCoV) on 12 January 2020 by World Health Organization (WHO). The Chinese scientists rapidly isolated a SARS-CoV-2 from a patient within a short time on 7 January 2020 and came out to genome sequencing of the SARS-CoV-2 [1]. As of 29 March 2020, a total of 81,439 cases of COVID-19 have been confirmed in mainland China including 3,300 deaths [2]. Studies estimated the basic reproduction number (R0) of SARS-CoV-2 to be around 2.2 [3], or even more (range from 1.4 to 6.5) [4], and familial clusters of pneumonia [5] outbreaks add to evidence of the epidemic COVID-19 steadily growing by human-to-human transmission. Coronavirus disease 2019 (COVID-19) is a respiratory illness that can spread from person to person. The virus that causes COVID-19 is a novel coronavirus that was first identified during an investigation into an outbreak in Wuhan, China. [6] However, if we compare the case ratio and the death ratio there is a difference when compared India with other. For example Italy has more social interactions and COVID-19 mortality is still high. In contrast, Japan had some of the earlier cases, but the mortality is low despite not having adopted some the more restrictive social isolation measurements. These differences are due to the medicinal standards implemented by the countries